Supplementary Figure 1 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis | Synapse
July 15, 2025
Supplementary Figure 1 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis
Key Points
MAIN FINDING: XPO1 expression impacts colorectal cancer outcomes, particularly in microsatellite stable variants.
KEY EVIDENCE: Overexpression of XPO1 correlates with poorer prognosis in MSS colorectal cancer cases.
APPROACH: Analysis of XPO1 levels across various stages of colorectal cancer was conducted.
SIGNIFICANCE: Understanding XPO1's role may guide therapeutic strategies to improve colorectal cancer prognosis.
Abstract
Supplementary Figure 1. XPO1 expression is similar amongst all stages of CRC and overexpression trends towards worst prognosis in MSS CRC.